Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care.

Riddle MC, Blonde L, Gerstein HC, Gregg EW, Holman RR, Lachin JM, Nichols GA, Turchin A, Cefalu WT.

Diabetes Care. 2019 Jun;42(6):1136-1146. doi: 10.2337/dci19-0020.

PMID:
31666233
2.

Response to Comment on Riddle et al. Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care 2019;42:1136-1146.

Riddle MC, Cefalu WT, Gregg EW.

Diabetes Care. 2019 Nov;42(11):e184. doi: 10.2337/dci19-0038. No abstract available.

PMID:
31636151
3.

The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study.

Riddle MC, Gerstein HC.

Diabetes Care. 2019 Jul;42(7):1159-1161. doi: 10.2337/dci19-0023. No abstract available.

PMID:
31221692
4.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.

PMID:
31189511
5.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.

PMID:
31189509
6.

More Evidence for a Prevention-Related Indication for Metformin: Let the Arguments Resume!

Cefalu WT, Riddle MC.

Diabetes Care. 2019 Apr;42(4):499-501. doi: 10.2337/dci18-0062. No abstract available.

PMID:
30894381
7.

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC.

Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12.

8.

Diabetes Care in 2019-Who, Why, What, and How?

Riddle MC.

Diabetes Care. 2019 Feb;42(2):181-182. doi: 10.2337/dci18-0059. No abstract available.

PMID:
30665961
9.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.

Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

J Diabetes Res. 2018 Dec 16;2018:1631263. doi: 10.1155/2018/1631263. eCollection 2018.

10.

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?

Riddle MC, Cefalu WT.

Diabetes Care. 2018 Dec;41(12):2444-2447. doi: 10.2337/dci18-0041. No abstract available.

PMID:
30459245
11.

Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.

Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P.

Diabetes Care. 2018 Nov;41(11):2346-2352. doi: 10.2337/dc18-1091. Epub 2018 Sep 13.

PMID:
30213882
12.
13.

Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?

Buse JB, D'Alessio DA, Riddle MC.

Diabetes Care. 2018 Aug;41(8):1560-1562. doi: 10.2337/dci18-0025. Epub 2018 Jun 25. No abstract available.

14.

Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology.

Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L.

Diabetes Care. 2018 Jul;41(7):1327-1329. doi: 10.2337/dci18-0035. No abstract available.

PMID:
29934474
15.

Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.

Terauchi Y, Riddle MC, Hirose T, Koyama M, Cheng X, Takahashi Y, Bolli GB.

Diabetes Obes Metab. 2018 Nov;20(11):2541-2550. doi: 10.1111/dom.13414. Epub 2018 Jul 16.

16.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
17.

The Cost of Diabetes Care-An Elephant in the Room.

Riddle MC, Herman WH.

Diabetes Care. 2018 May;41(5):929-932. doi: 10.2337/dci18-0012. No abstract available.

PMID:
29678864
18.

Scientific Exploration With Continuous Monitoring Systems: An Early Assessment of Arrhythmias During Hypoglycemia.

Riddle MC, Miller ME.

Diabetes Care. 2018 Apr;41(4):664-666. doi: 10.2337/dci18-0009. No abstract available.

PMID:
29559453
19.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Riddle MC, Bolli GB, Avogaro A, Gimenez Álvarez M, Merino-Trigo A, Boëlle-Le Corfec E, Home PD.

Diabetes Metab. 2018 Sep;44(4):333-340. doi: 10.1016/j.diabet.2017.12.001. Epub 2017 Dec 11.

20.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

21.

In an Anniversary Year, Diabetes Care Takes a Selfie.

Riddle MC.

Diabetes Care. 2018 Jan;41(1):3-5. doi: 10.2337/dci17-0054. No abstract available.

PMID:
29263191
22.

Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions.

Riddle MC, Gerstein HC, Cefalu WT.

Diabetes Care. 2017 Dec;40(12):1611-1613. doi: 10.2337/dci17-0049. No abstract available.

PMID:
29162581
23.

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

Circulation. 2017 Oct 17;136(16):1560-1562. doi: 10.1161/CIRCULATIONAHA.117.029503. No abstract available.

PMID:
29038210
24.

Diabetes Research and Care Through the Ages.

Zinman B, Skyler JS, Riddle MC, Ferrannini E.

Diabetes Care. 2017 Oct;40(10):1302-1313. doi: 10.2337/dci17-0042.

PMID:
28931706
25.

Insulin resistance and cardiovascular outcomes in the ORIGIN trial.

Gerstein HC, Ferrannini E, Riddle MC, Yusuf S; ORIGIN Trial Investigators.

Diabetes Obes Metab. 2018 Mar;20(3):564-570. doi: 10.1111/dom.13112. Epub 2017 Oct 8.

PMID:
28895655
26.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8.

27.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD; EDITION 3 study investigators.

Diabetes Metab. 2017 Sep;43(4):351-358. doi: 10.1016/j.diabet.2017.04.007. Epub 2017 Jun 13.

28.

Erratum. Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target! Diabetes Care 2017;40:291-300.

Riddle MC.

Diabetes Care. 2017 Aug;40(8):1133. doi: 10.2337/dc17-er08b. Epub 2017 Jun 14. No abstract available.

29.

Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option.

Lipska KJ, Hirsch IB, Riddle MC.

JAMA. 2017 Jul 4;318(1):23-24. doi: 10.1001/jama.2017.6939. No abstract available.

PMID:
28604935
30.

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T; REWIND Trial Investigators.

Diabetes Obes Metab. 2018 Jan;20(1):42-49. doi: 10.1111/dom.13028. Epub 2017 Jul 14.

31.

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L.

J Am Heart Assoc. 2017 May 29;6(6). pii: e004743. doi: 10.1161/JAHA.116.004743.

32.

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

Terauchi Y, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T; EDITION JP 2 study group.

Diabetes Metab. 2017 Oct;43(5):446-452. doi: 10.1016/j.diabet.2017.03.001. Epub 2017 Apr 19.

PMID:
28433560
33.

Modern Sulfonylureas: Dangerous or Wrongly Accused?

Riddle MC.

Diabetes Care. 2017 May;40(5):629-631. doi: 10.2337/dci17-0003. No abstract available.

PMID:
28428320
34.

Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!

Riddle MC.

Diabetes Care. 2017 Mar;40(3):291-300. doi: 10.2337/dc16-2380. Review. Erratum in: Diabetes Care. 2017 Jun 14;:.

PMID:
28223444
35.

Diabetes Care: "Taking It to the Limit One More Time".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC.

Diabetes Care. 2017 Jan;40(1):3-6. doi: 10.2337/dc16-2326. No abstract available.

36.

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).

Matsuhisa M, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group.

Diabetes Res Clin Pract. 2016 Dec;122:133-140. doi: 10.1016/j.diabres.2016.10.002. Epub 2016 Oct 13.

PMID:
27835765
37.
38.

Diabetes Care: "Lagniappe" and "Seeing Is Believing"!

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L.

Diabetes Care. 2016 Jul;39(7):1069-71. doi: 10.2337/dc16-0891. Epub 2016 Jun 9. No abstract available.

39.

Building Momentum: Taking on the Real “Issues” of Diabetes Care!

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L.

Diabetes Care. 2016 Jan;39(1):10-12. doi: 10.2337/dc15-2315. No abstract available.

40.

Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory".

Cefalu WT, Rosenstock J, LeRoith D, Blonde L, Riddle MC.

Diabetes Care. 2016 May;39(5):664-7. doi: 10.2337/dc16-0405. No abstract available.

41.

Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability.

Riddle MC.

Diabetes Care. 2016 Apr;39(4):499-501. doi: 10.2337/dc15-2754. No abstract available.

PMID:
27208365
42.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Järvinen H.

Diabetes Technol Ther. 2016 Apr;18(4):252-7. doi: 10.1089/dia.2015.0290. Epub 2016 Feb 3.

43.

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).

Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group.

Diabetes Obes Metab. 2016 Apr;18(4):375-83. doi: 10.1111/dom.12619. Epub 2016 Feb 1.

44.
45.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

46.

Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress".

Cefalu WT, Rosenstock J, LeRoith D, Riddle MC.

Diabetes Care. 2015 Dec;38(12):2200-3. doi: 10.2337/dci15-0023. No abstract available.

47.

Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.

Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Solomon S; ACCORD Investigators.

Diabetes Care. 2015 Nov;38(11):2000-8. doi: 10.2337/dc15-0598. Epub 2015 Oct 13.

48.
49.

Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!

Cefalu WT, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L.

Diabetes Care. 2015 Jul;38(7):1177-80. No abstract available.

50.

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M, Riddle MC.

Diabetes Obes Metab. 2015 Dec;17(12):1142-9. doi: 10.1111/dom.12532. Epub 2015 Sep 14.

Supplemental Content

Loading ...
Support Center